NASDAQ · Biotechnology · USD
RenovoRx, Inc. (RNXT) Stock Analysis
RenovoRx, Inc. (RNXT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RNXT Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.20
- Previous Close
- $1.20
- Day's Range
- 1.20–1.29
- 52-Week Range
- 0.70–2.59
- Volume
- 403.24K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.97
Valuation
- Market Cap
- $55.51M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 28.09
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.31
Financials (FY)
- Revenue (FY)
- $1.12M+2,511.63%
- Net Income (FY)
- −$11.17M
- Shares Outstanding
- 45.13M
- 1-Year Return
- +3.36%
Dividend and dates
- Earnings Date
- November 9, 2026estimated
- Avg Volume
- 806.26K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RNXT closed at $1.23, +3.36% over 1 year.
RenovoRx, Inc. (RNXT) has a market capitalization of $55.51M.
In fiscal 2025, RNXT reported revenue of $1.12M.
RNXT Stock Return by Calendar Year
RenovoRx, Inc. (RNXT) return since Aug 2021: what $10,000 became
- 1 year
- $10,000 $10,336
- +3.36%
- 5 years
- $10,000 $2,092
- −79.08%
- Since Aug 2021
- $10,000 $1,694
- −83.06%
If you had invested $10,000 in RenovoRx, Inc. (RNXT) at the close on August 26, 2021, the earliest close on record here, it would have been worth $1,694 at the close on October 21, 2026: −83.06% in total, −29.15% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +46.43% |
| 2025 | −34.88% |
| 2024 | −43.67% |
| 2023 | −2.55% |
| 2022 | −51.45% |
| 2021 (partial year) | −33.33% |
As of October 21, 2026.
RNXT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $1.12M | −$11.17M | −994.5% |
| 2024 | $43.00K | −$8.81M | −20,497.7% |
| 2023 | $0.00 | −$10.23M | — |
| 2022 | $0.00 | −$9.89M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $1.12M | $796.00K | −$12.51M | −$11.17M | −994.5% |
| 2024 | $43.00K | $43.00K | −$10.97M | −$8.81M | −20,497.7% |
| 2023 | $0.00 | $0.00 | −$11.40M | −$10.23M | — |
| 2022 | $0.00 | — | −$9.95M | −$9.89M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
RNXT Valuation vs Biotechnology Median
Median of 608 stocks| Metric | RNXT | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 28.09 | 13.30 | 111% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
YahooRenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
BenzingaRenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
YahooRenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
BenzingaRenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
InvestorsHubRenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
Yahoo
All 12 articles ↓Show fewer ↑
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
BenzingaRenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
BenzingaRenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
BenzingaRenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est
BenzingaRenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
BenzingaEXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B